Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer
BRISBANE, Calif.--(BUSINESS WIRE)--Sep. 30, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer. Dr. Cockroft will oversee all clinical development activities and operations and will report to the Executive Vice President of Research and Development.
“Bettina brings over 20 years of clinical development experience, having worked across multiple therapeutic areas and leading programs in several countries,” said Adrian Woolfson, BM., B.Ch., Ph.D., Executive Vice President, Research and Development. “This is an important time to welcome Bettina to Sangamo, as we expect a steady flow of readouts from our ongoing clinical trials and expect to initiate additional trials in the coming year. We look forward to Bettina’s contributions and believe she will be a key player in helping us realize our mission of translating our groundbreaking science into genomic medicines that transform patients’ lives.”